Abstract
Pulmonary hypertension specific therapies (PHTx) are intended for WHO Group 1 pulmonary hypertension (PAH). PH related to respiratory diseases (Group 3) may benefit from PHTx; however, there are no clear metrics for appropriate patient selection.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
